Therapeutic Evaluation of Recombinant Human Erythropoietin (rhEPO) In Isoproterenol Induced Myocardial Infarction in Wistar Rats

OPEN-ACCESS PEER-REVIEWED

¹T. Hari Prasad, ²A.G. Narayana Swamy, ³S. Senthilkumar, ⁴B. V. Surendra, ⁵R. Vijayaraghavan

¹Assistant Professor, Department of Physiology, Viswabharathi Medical College & Hospital, Kurnool – 518467, Andhra Pradesh, India., Research Scholar, Department of Research & Development SIMATS, Chennai – 602105, Tamilnadu, India.

²Professor, Department of Cardiology, Saveetha Medical College and Hospital, Thandalam, Chennai – 602 105, India

³Associate Professor, Department of Research and Development, Saveetha Institute of Medical and Technical Sciences, Chennai – 602 105, Tamil Nadu, India, Associate professor, department of Biosciences, Institute of Biotechnology, SIMATS School of Engineering, Saveetha institute of Medicine and Technical sciences, Chennai-602105, Tamilnadu, India

⁴Associate Professor, Department of Physiology, Viswabharathi Medical College & Hospital, Kurnool – 518467, Andhra Pradesh, India.

⁵Former Director-Research, Department of Research and Development, Saveetha Institute of Medical and Technical Sciences, Chennai – 602 105, Tamil Nadu, India

Download PDF

Abstract

Recombinant human erythropoietin (rhEPO) is an effective treatment for myocardial infarction (MI) by promoting cardiac repair. However, additional investigations are required to determine its therapeutic value. The present study aims to investigate the effect of rhEPO in isoproterenol- (ISO-) induced myocardial infarction in Wistar rats. The efficacy of EPO pre- and post-therapy, as evaluated by histology, histomorphometry, and immunohistochemistry analysis, forms the novelty of the present study. Adult male Wistar Albino rats were taken in four groups (Group1- control, Group2 – ISO induced MI, Group 3-ten days rhEPO pre-treatment + ISO induction, and Group4-ISO induction + single dose rhEPO post-treatment), respectively. While Group 1 rats served as normal controls, Group 2 rats received a single ISO-isoproterenol (75 mg/kg b.w) on the final day of the trial. The rats in Group 3 received rhEPO (5000 IU/kg i.p) injections once daily for 10 days and a single dosage of isoproterenol (75 mg/kg i.p) on the 10th day. The group 4 rats received a single injection of ISO (75 mg/kg i.p.) followed by a single injection of rhEPO (5000 IU/kg i.p.) at a 2-hour interval. The rats were sa`crificed, and samples were taken for further study. The therapeutic potential of rhEPO, i.e., ten days’ pre-treatment before ISO induction, as well as the efficacy of a single dose of rhEPO post-treatment following ISO-induced myocardial damage, was investigated by immunohistochemical alterations of collagen, caspase1, p-SMAD3, and ASC proteins in the heart tissue. The histo pathological changes were evaluated in the heart tissues of study group rats. The immuno histo chemistry modifications reveal that erythropoietin post-therapy is more effective than pre-treatment against MI. However, histological abnormalities in cardiac tissues confirm it. As a result, rhEPO is more effective against MI after treatment than before treatment.

Keywords: Isoproterenol; Myocardial infarction; Erythropoietin; Wistar rats; ASC Protein.

References

[1]. Zambahari R, Rajadurai J, Fong A, Chandran A, Hooi CG, Salleh NA, et al. Malaysia CPG for STEMI. ASEAN Heart J. 2014; 1:1-6.

[2]. Libby P. Current Concepts of the Pathogenesis of the Acute Coronary Syndromes. Circulation 2001; 104: 365–72.

[3]. Kareem MA, Krushna GS, Hussain SA, Devi KL. Effect of aqueous extract of nutmeg on hyperglycaemia, hyperlipidaemia and cardiac histology associated with isoproterenol-induced myocardial infarction in rats. Trop J Pharm Res 2009;8(4): 337-344.

[4]. Lu, L., Liu, M., Sun, R. et al. Myocardial Infarction: Symptoms and Treatments. Cell BiochemBiophys 2015, 72: 865–867.

[5]. Rona, G., Kahn, D. S., Chappel, C. I. Studies on infarct-like myocardial necrosis produced by isoproterenol: A review. Rev Can Biol 1963, 22:241–55.

[6]. NagoorMeeran, M., StanelyMainzen Prince, P. Protective effects of N-acetyl cysteine on membrane-bound adenosine triphosphatases and minerals in isoproterenol-induced myocardial-infarcted rats: an in vivo and in vitro study. J BiochemMolToxicol 2012, 26: 276–281.

[7]. Wexler, B. C., and Greenberg, B. P. (1978). Protective effect of clofibrate on isoproterenol-induced myocardial infarction in arterio-sclerotic and nonarterio- sclerotic rats. Atherosclerosis 1978, 29: 373–75.

[8]. Carey, I., DeWilde, S., Shah, S., Harris, T., Whincup, P., Cook, D. Statin use after first myocardial infarction in UK men and women from 1997 to 2006: Who started and who continued treatment? NutrMetabCardiovasc Dis 2012, 22: 400–408.

[9]. Rajadurai, M., &StanelyMainzen Prince, P. Preventive effect of naringin on cardiac markers, electrocardiographic patterns and lysosomal hydrolases in normal and isoproterenol-induced myocardial infarction in Wistar rats. Toxicology 2007, 230(2-3), 178–188

[10]. Stein, A. &Ott, I. Erythropoietin in Myocardial Infarction: Experimental Evidence and Clinical Studies. European J. of Cardiovascular Medicine 2011, Vol. I, Issue III, ISSN: 2042 – 4884.

[11]. Gao D, Ning N, Niu X, Dang Y, Dong X, Wei J, Zhu C. Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Am. Heart J. 2012, 164:715-727.

[12]. Brines, M., Grasso, G., Fiordaliso, F., Sfacteria, A., Ghezzi, P., Fratelli,et al.,. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit hetero receptor. Proc. Natl. Acad. Sci. USA 2004, 101: 14907–14912.

[13]. Sasaki H, Ochi N, Dell A, Fukuda M. Site-specific glycosylation of human recombinant erythropoietin: Analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry. Biochemistry. 1988; 27:8618–8626.

[14]. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. Faseb J. 2004;18:1031–1033.

[15]. Said MA, Nafeh NY. Cardioprotective Effect of Erythropoietin on Isoprenaline Induced Myocardial Infarction in Rats. Benha Medical Journal. 2014; 31(2): 399-415

[16]. Dianita R, Jantan I, Amran AZ, Jalil J. Protective effects of Labisiapumila var. alata on biochemical and histopathological alterations of cardiac muscle cells in isoproterenol-induced myocardial infarction rats. Molecules. 2015 Mar 16; 20(3):4746-63.

[17]. Cheng G, Zhang J, Jia S, Feng P, Chang F, Yan L, Gupta P, Wu H. Cardioprotective Effect of Gossypin Against Myocardial Ischemic/Reperfusion in Rats via Alteration of Oxidative Stress, Inflammation and Gut Microbiota. J Inflamm Res. 2022 Mar 5;15:1637-1651.

[18]. Goyal SN, Sharma C, Mahajan UB, Patil CR, Agrawal YO, Kumari S, Arya DS, Ojha S. Protective Effects of Cardamom in Isoproterenol-Induced Myocardial Infarction in Rats. Int J Mol Sci. 2015 Nov 17; 16(11):27457-69.

[19]. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003 Sep 1;59(3):538-48.

[20]. Santhanam AV, d’Uscio LV, Katusic ZS. Cardiovascular effects of erythropoietin an update. AdvPharmacol. 2010; 60:257-85.

[21]. Ma, B. X., Li, J., Li, H., & Wu, S. S. Recombinant Human Erythropoietin Protects Myocardial Cells from Apoptosis via the Janus-Activated Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway in Rats with Epilepsy. Current therapeutic research, clinical and experimental 2015, 77: 90–98.

[22]. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, Talan MI. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl AcadSci U S A. 2003;100(20):11612–11617.

[23]. Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, Zweier JL, Semenza GL. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003,108: 79–85.

[24]. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, Matsumoto A, Stamler JS, Koch WJ. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J BiolChem 2004, 279: 20655–20662.

[25]. Lipsic E, van der Meer P, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J CardiovascPharmacol 2004, 44: 473–479.

[26]. Van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am CollCardiol 2005, 46: 125–133.

[27]. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112: 999–1007, 2003.

[28]. Dawn Z Eichenfield, Ty Dale Troutman, Verena M Link, Michael T Lam, Han Cho, David Gosselin, Nathanael J Spann, Hanna P Lesch, Jenhan Tao, Jun Muto, Richard L Gallo, Ronald M Evans, Christopher K Glass .Tissue damage drives co-localization of NF-κB, Smad3, and Nrf2 to direct Rev-erb sensitive wound repair in mouse macrophages. eLife 2015, 5:e13024 .

[29]. Khalil H, Kanisicak O, Prasad V. et al. Fibroblast-specific TGF-beta-Smad2/3 signaling underlies cardiac fibrosis. J Clin Invest. 2017;127:3770-3783

[30]. Petrov, V. V., Fagard, R. H., &Lijnen, P. J. (2002). Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension (Dallas, Tex. : 1979, 39(2) : 258–263.

[31]. Ma H, Killaars AR, DelRio FW, Yang C, Anseth KS. Myofibroblastic activation of valvular interstitial cells is modulated by spatial variations in matrix elasticity and its organization.Biomaterials. 2017; 131:131–144.

[32]. Gu H, Duan Y, Li S, Wang Q, Zhen W, Zhang W, Zhang Y, Jiang M, Wang C. miR-96-5p regulates myocardial infarction-induced cardiac fibrosis via Smad7/Smad3 pathway. ActaBiochimBiophys Sin (Shanghai) 2022 , Dec 25;54(12):1874-1888.

[33]. Albadrani GM, BinMowyna MN, Bin-Jumah MN, El-Akabawy G, Aldera H, Al-Farga AM. Quercetin prevents myocardial infarction adverse remodeling in rats by attenuating TGF-β1/Smad3 signaling: Different mechanisms of action. Saudi J Biol Sci. 2021 May; 28(5):2772-2782.

[34]. Ni J, Shi Y, Li L, Chen J, Li L, Li M, Zhu J, Zhu Y, Fan G. Cardioprotection against Heart Failure by Shenfu Injection via TGF-β/SmadsSignaling Pathway. Evid Based Complement Alternat Med. 2017;2017:7083016.

[35]. Han A, Lu Y, Zheng Q, Zhang J, Zhao Y, Zhao M, Cui X. Qiliqiangxin Attenuates Cardiac Remodeling via Inhibition of TGF-β1/Smad3 and NF-κBSignaling Pathways in a Rat Model of Myocardial Infarction. Cell PhysiolBiochem. 2018; 45(5):1797-1806.

[36]. Li SC, Ma LN, Chen J, Li YK. [Effect of allicin on myocardial fibrosis after myocardial infarction in rats and its relationship with TGFβ/Smads signal transduction]. ZhongguoZhong Yao ZaZhi. 2016 Jul;41(13):2517-2521. Chinese. doi: 10.4268/cjcmm20161324. PMID: 28905578.

[37]. Ma J, Li ZY, Liang XP, Guo CX, Lu PP, Ma LH. Xinfuli Granule improves post-myocardial infarction ventricular remodeling and myocardial fibrosis in rats by regulating TGF-β/Smadssignaling pathway. J GeriatrCardiol. 2017 May;14(5):301-307.

[38]. Ghoneim M A, Hassan AI, Mahmoud MG, Asker MS. Protective Effect of Adansoniadigitata against Isoproterenol-Induced Myocardial Injury in Rats. Animal biotechnology 2016, 27(2), 84–95.

[39]. Chen Y, Surinkaew S, Naud P, Qi XY, Gillis MA, Shi YF, Tardif JC, Dobrev D, Nattel S. JAK-STAT signalling and the atrial fibrillation promoting fibrotic substrate. Cardiovasc Res. 2017 Mar 1;113(3):310-320.

[40]. Liu D, Tian X, Liu Y, Song H, Cheng X, Zhang X, Yan C, Han Y. CREG ameliorates the phenotypic switching of cardiac fibroblasts after myocardial infarction via modulation of CDC42. Cell Death Dis. 2021 Apr 6;12(4):355.

[41]. Vilahur G, Juan-Babot O, Peña E, Oñate B, Casaní L, Badimon L. Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J Mol Cell Cardiol. 2011 Mar;50(3):522-33.

[42]. Liu Z, Chen X, Ye T, Wan W, Yu Y, Zhang C, Yang B. Pinocembrin alleviates the susceptibility to atrial fibrillation in isoproterenol-induced rats. BiochemBiophys Res Commun. 2022 Dec 25;636(Pt 1):33-40

[43]. Weng S, Zhu X, Jin Y, Wang T, Huang H. Protective effect of erythropoietin on myocardial infarction in rats by inhibition of caspase-12 expression. ExpTher Med. 2011 Sep;2(5):833-836.

[44]. Pan XC, Liu Y, Cen YY, Xiong YL, Li JM, Ding YY, Tong YF, Liu T, Chen XH, Zhang HG. Dual Role of Triptolide in Interrupting the NLRP3 Inflammasome Pathway to Attenuate Cardiac Fibrosis. Int J Mol Sci. 2019 Jan 16;20(2):360.